Keertan Dheda

7 ta ish

University of Cape Town

1. Treatment correlates of successful outcomes in pulmonary multidrug-resistant tuberculosis: an individual patient data meta-analysis

   Nafees Ahmad, Shama D. Ahuja, Onno W. Akkerman +97

   Sharh maqolaOAOchiq kirish20184 iqtibos

   ABIABI:AkademIndex/2026.other.034216

2. What is new in the WHO consolidated guidelines on drug-resistant tuberculosis treatment?

   Surendra K. Sharma, Keertan Dheda

   Tahririyat maqolasi20193 iqtibos

   ABIABI:AkademIndex/2026.other.360277

3. Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

   Merryn Voysey, Sue Ann Costa Clemens, Shabir A. Madhi +97

   Maqola20203 iqtibos

   ABIABI:AkademIndex/2026.other.554494

4. The implications of using an inappropriate reference gene for real-time reverse transcription PCR data normalization

   Keertan Dheda, Jim F. Huggett, Jian-jun Chang +5

   Maqola20052 iqtibos

   ABIABI:AkademIndex/2026.other.063185

5. Recent controversies about <scp>MDR</scp> and <scp>XDR‐TB</scp>: <scp>G</scp>lobal implementation of the <scp>WHO</scp> shorter <scp>MDR‐TB</scp> regimen and bedaquiline for all with <scp>MDR‐TB</scp>?

   Keertan Dheda, Helen Cox, Aliasgar Esmail +3

   Sharh maqolaOAOchiq kirish20172 iqtibos

   ABIABI:AkademIndex/2026.other.130259

6. Management of drug-resistant tuberculosis

   Christoph Lange, Keertan Dheda, Dumitru Chesov +3

   Sharh maqolaOAOchiq kirish20192 iqtibos

   ABIABI:AkademIndex/2026.other.195704

7. The epidemiology, pathogenesis, transmission, diagnosis, and management of multidrug-resistant, extensively drug-resistant, and incurable tuberculosis

   Keertan Dheda, Tawanda Gumbo, Gary Maartens +39

   Sharh maqola20172 iqtibos

   ABIABI:AkademIndex/2026.other.279676